Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
SIPPET study results published in the “New England Journal of Medicine”
This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world
Kedrion Biopharma for Mother’s Day
We are committed to helping eliminate Rh disease worldwide by supporting initiatives like CURhE
CURhE, Global Alliance for mother and child healthcare
Kedrion among the founding members. The aim is Rh disease eradication
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
A brand new location for KEDPlasma donors in the very center of Fürth
Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide
KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US
The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial
Strategic agreement between Kedrion and Kamada for its clinical development and marketing
Kedrion supports Fondazione Paracelso’s activities in Afghanistan
Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries
Kedrion Notes 2019 Tender Offer results
Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000